Paraneoplastic Encephalomyelitis

Back

Practice Essentials

Paraneoplastic encephalomyelitis (PEM) is a multifocal inflammatory disorder of the central nervous system (CNS) associated with remote neoplasia.[1] Frequently, the disorder is accompanied by subacute sensory neuronopathy (SSN) due to involvement of the dorsal root ganglia. Anti-Hu antibodies may be detected in both of these conditions. Although various malignancies have been reported in PEM, 80% of cases are associated with bronchial cancer, typically small cell lung carcinoma.[2] Neurologic manifestations commonly precede the diagnosis of cancer, although variable presentations have been reported. Symptoms usually progress over the course of weeks to months, reaching a plateau of neurologic disability. Neurologic impairment may be more debilitating than the associated cancer. No effective therapeutic approaches have been established, although immunosuppressive therapies are commonly used. See the images below.



View Image

Paraneoplastic encephalomyelitis.



View Image

Paraneoplastic encephalomyelitis.

Pathophysiology

Neurologic dysfunction probably results from an autoimmune reaction directed against onconeural antigens in the human nervous system. Polyclonal immunoglobulin G (IgG) anti-Hu antibodies or type 1 antineuronal nuclear antibodies are most prevalent (~50%), although several other circulating autoantibodies have been identified. Some patients have no identifiable paraneoplastic antibodies. These markers of paraneoplasia have an undetermined pathogenic role. Cytotoxic T cell–mediated neuronal damage is suspected, although no animal models have been developed to confirm this.[3]

Almost all cases of PEM with anti-Hu antibodies are related to small-cell lung carcinoma. These antibodies react with a group of 35- to 40-kilodalton neuronal RNA-binding proteins, including HuD[4] , PLE21/HuC, and Hel-N1. Nuclear and cytoplasmic staining of CNS neurons demonstrates the presence of these antibodies. A ubiquitous protein, HuR, is also an antigenic target. The neuronal proteins are homologous to the embryonic lethal abnormal visual (ELAV) protein in Drosophila species. Anti-Hu antibodies may alter the production of these proteins, which are essential for the development, maturation, and maintenance of the vertebrate nervous system. Intrathecal synthesis of anti-Hu antibodies may represent an autoimmune cross-reaction with neurologic tissue, triggered by a remote carcinoma. Recent work has focused on the detection of neuron-specific ELAV mRNA in peripheral blood of SCLC patients using real-time quantitative polymerase chain reaction (PCR).[5]

In a recent report, a subset of patients with limbic encephalitis associated with a systemic neoplasm previously attributed to antibodies against voltage gated potassium channel antibodies actually recognize LGI1 protein complex epitopes and do not represent a channelopathy. The authors propose the term limbic encephalitis associated with LGI1 antibodies.[6]

Other PEM antibodies include anti-CV2, anti-Yo, anti-Ma1, anti-Ta or anti-Ma2, anti-LGI1, and several other atypical antibodies. The targets of such antibodies may be quite varied, including neuropil and intraneuronal sites.

Nonneuronal autoantibodies, such as antinuclear antibodies and anticytoplasmic antibodies, are frequently detected in cases with anti-Hu antibodies or anti-Yo antibodies. The presence of such nonneuronal autoantibodies, however, does not correlate with particular clinical characteristics.[7]

Voltage-gated potassium channel antibodies may be associated with nonparaneoplastic limbic encephalitis.

Recent reports have noted detection of the prion-related 14-3-3 protein[8] and of herpes simplex virus[9] by PCR in the cerebrospinal fluid (CSF) of patients with PEM. The significance of these findings is unclear.

Epidemiology

Frequency

The incidence of PEM is unknown. PEM affects approximately 0.4% of patients with bronchial carcinoma. Increased recognition of clinical manifestations may provide estimates of incidence in the future.

Mortality/Morbidity

PEM has a variable and unpredictable course.

Progressive evolution of neurologic dysfunction may lead to coma and death in a few patients.

Most patients experience severe neurologic impairment with susceptibility to related medical complications.

Race-, sex-, and age-related demographics

No racial predilection has been reported.

Anti-Hu–associated PEM has a slight female predominance.[10]

PEM occurs most frequently in middle-aged or older adults with small-cell lung carcinoma. It may occur in younger individuals with other types of cancer.

History

The neurologic manifestations of PEM precede the diagnosis of cancer in 80% of cases. Typically, a subacute onset of neurologic symptoms is followed by progression over weeks to months, finally reaching a plateau of neurologic impairment. The clinical presentation reflects the distribution of this multifocal inflammatory condition. Specific clinical syndromes have been described, although considerable overlap exists.

Physical

Physical examination findings assist in the localization of clinical symptoms and anatomical classification of specific paraneoplastic syndromes.

Causes

Smoking is a potential risk factor, as most cases are associated with small-cell lung cancer.

Family history of cancer is another risk factor.

Laboratory Studies

Serum and CSF paraneoplastic antibody panel - Identify paraneoplastic etiology and detect autoimmune markers (eg, high levels of autoantibodies to glutamic acid decarboxylase [GAD-ab][14] ).

Cerebrospinal fluid

Cell count, protein, glucose, oligoclonal bands, IgG synthesis rate, cytology, and PCR for herpes simplex virus and varicella zoster virus.

Assess for differential diagnoses involving the central nervous system.

Serum tumor markers

Carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), prostate-specific antigen (PSA).

Evaluate for an underlying malignancy.

Other tests

Other tests that may prove helpful for diagnosis include the following:

Imaging Studies

Head CT provides limited information regarding PEM but allows for preliminary evaluation of differential diagnoses such as herpes simplex encephalitis or intracranial metastatic disease. Hypodensity on CT scan may be seen in chronic stages of paraneoplastic encephalomyelitis (PEM).

Brain MRI may help to rule out the differential diagnoses. Usually, MRI in a patient with PEM is unremarkable, although T2-weighted hyperintensity may be noted in mesial temporal lobes and associated limbic structures (see following image). Posterior thalamic T2 hyperintensity, or the "pulvinar sign[15] ," may be present. Contrast enhancement may be demonstrated with subsequent development of atrophy and gliosis, reflecting the dynamic evolution of inflammatory injury. MR spectroscopy of the brain may add further information.



View Image

Mesial temporal hyperintensity demonstrated on T2-weighted (left) and fluid-attenuated inversion recovery (FLAIR, right) MRI.

Positron emission tomography (PET) may illustrate hypermetabolism of limbic regions during the active phase of disease, supplanted by hypometabolism in the chronic phase. Whole body PET may also identify the primary lesion.

Myelography may demonstrate an enlarged spinal cord associated with inflammation.

The following studies may be done to identify an underlying malignancy:

Other Tests

Electroencephalography (EEG) may reveal focal temporal or diffuse paroxysmal sharp waves and spikes, and/or slowing.

Electromyography/nerve conduction studies of subacute sensory neuronopathy may reveal selective damage of sensory pathways with limited detection of H waves and preservation of motor nerve velocities and F waves. Studies of myelitis may exhibit motor denervation.

Procedures

Lumbar puncture is essential for determination of the CSF profile and detection of intrathecal paraneoplastic antibodies.

Diagnostic imaging modalities may help avoid the need for brain biopsy in some cases.

Histologic Findings

The neuropathologic findings are typically more extensive than the degree of neurologic manifestations. Gross examination of the brain is usually unremarkable. Neuronal degeneration, gliosis, and an inflammatory infiltrate may be demonstrated throughout the brain. Perivascular and interstitial infiltrates are composed of B lymphocytes and cluster of differentiation 4 (CD4+) and CD8+ T lymphocytes, with microglial proliferation and neuronophagia. Limbic structures are particularly vulnerable, with prominent involvement of the hippocampus, amygdala, parahippocampus, cingulate cortex, insular cortex, and basal frontal lobes. Similar changes may be noted in the diencephalon, brain stem, deep cerebellar nuclei, spinal cord, dorsal root ganglia, sympathetic ganglia, and myenteric plexus.

Medical Care

Timely diagnosis of paraneoplastic encephalomyelitis (PEM) is critical to allow for appropriate treatment of the underlying malignancy.[17]

Surgical Care

Surgical treatment options do not exist other than for the primary cancer.

Consultations

Consultation with the following may prove useful:

Diet

Specific dietary requirements do not exist, although aspiration precautions may be necessary in debilitated patients.

Activity

The presence of neurologic deficits and postural hypotension may necessitate supervision of activity or precautions to avoid falls.

Medication Summary

Although no effective treatment is available, immunosuppressive therapies are frequently used.[20] Immunosuppressive medications include corticosteroids, cyclophosphamide, and intravenous immunoglobulin (IVIG). Recent trials have included rituximab as a treatment for this condition.[21] Anticonvulsants are used for seizure prophylaxis.

Methylprednisolone (Solu-Medrol, Medrol, Adlone, Depo-Medrol)

Clinical Context:  Has anti-inflammatory properties. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Initial PO daily dosage variable, with subsequent dose modification based on clinical response. Constant monitoring may be necessary to adjust for changes in clinical status and environmental stressors. After long-term therapy, taper drug gradually.

Prednisone (Deltasone, Meticorten, Orasone)

Clinical Context:  Has anti-inflammatory properties. May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Initial PO daily dosage variable, with subsequent dose modification based on clinical response. Constant monitoring may be necessary to adjust for changes in clinical status and environmental stressors. After long-term therapy, taper drug gradually.

Class Summary

These agents modify autoimmune-mediated inflammation.

Cyclophosphamide (Cytoxan, Neosar)

Clinical Context:  Has immunosuppressive properties. Chemically related to nitrogen mustards. As alkylating agent, mechanism of action of active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells.

PO/IV daily dosage recommendations have not been formulated for treatment of PEM. Modify dose based on clinical response or degree of leukopenia.

Intravenous immunoglobulin (IVIG; Gamimune, Gammagard, Sandoglobulin, Gammar-P)

Clinical Context:  Neutralizes circulating antibodies through anti-idiotypic antibodies. Down-regulates proinflammatory cytokines, including IFN-gamma. Blocks Fc receptors on macrophages. Suppresses inducer T and B cells and augments suppressor T cells. Blocks complement cascade. May increase CSF IgG (10%).

IV dosage recommendations have not been formulated for treatment of PEM.

Class Summary

They cause immunosuppressive reduction in inflammation-mediated neurologic injury.

Fosphenytoin (Cerebyx)

Clinical Context:  Diphosphate ester salt of phenytoin acts as water-soluble prodrug of phenytoin. Following administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin. Phenytoin in turn stabilizes neuronal membranes and decreases seizure activity.

To avoid need to perform molecular weight-based adjustments when converting between fosphenytoin and phenytoin sodium doses, express dose as phenytoin sodium equivalents (PE). Although can be administered IV and IM, IV route is route of choice and should be used in emergency situations.

Concomitant administration of an IV benzodiazepine usually necessary to control status epilepticus. Full antiepileptic effect of phenytoin, whether given as fosphenytoin or parenteral phenytoin, is not immediate.

Class Summary

These agents are used for treatment and prophylaxis of seizures.

Further Outpatient Care

See the list below:

Further Inpatient Care

See the list below:

Inpatient & Outpatient Medications

See the list below:

Transfer

Rapid diagnosis of paraneoplastic encephalomyelitis (PEM) and evaluation of an underlying malignancy should be conducted at a center with neurologic expertise and diagnostic neuroradiologic modalities available.

Deterrence/Prevention

Preventive measures, such as smoking cessation, are focused on reducing the incidence of the associated malignancy.

Complications

See the list below:

Prognosis

The clinical course of PEM is unpredictable, although the titer of anti-Hu antibodies has been suggested as a prognostic indicator. Elevated titers have been associated with worse neurologic outcome and death.

Patient Education

Public education efforts should emphasize the dangers of smoking and increase awareness of paraneoplastic disorders.

Author

David S Liebeskind, MD, FAAN, FAHA, FANA, Professor of Neurology and Director, Neurovascular Imaging Research Core, Director, Vascular Neurology Residency Program, Department of Neurology, University of California, Los Angeles, David Geffen School of Medicine; Director, UCLA Outpatient Stroke and Neurovascular Programs; Director, UCLA Cerebral Blood Flow Laboratory; Associate Neurology Director, UCLA Stroke Center

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Jorge C Kattah, MD, Head, Associate Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria

Disclosure: Nothing to disclose.

Chief Editor

Stephen A Berman, MD, PhD, MBA, Professor of Neurology, University of Central Florida College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Frederick M Vincent, Sr, MD, Clinical Professor, Department of Neurology and Ophthalmology, Michigan State University Colleges of Human and Osteopathic Medicine

Disclosure: Nothing to disclose.

References

  1. Blaes F. Paraneoplastic neurological syndromes--diagnosis and management. Curr Pharm Des. 2012. 18(29):4518-25. [View Abstract]
  2. Shirafuji T, Kanda F, Sekiguchi K, Higuchi M, Yokozaki H, Tanaka K, et al. Anti-Hu-associated paraneoplastic encephalomyelitis with esophageal small cell carcinoma. Intern Med. 2012. 51(17):2423-7. [View Abstract]
  3. Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology. 2008 Sep 16. 71(12):930-6. [View Abstract]
  4. Benyahia B, Liblau R, Merle-Beral H, et al. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999 Feb. 45(2):162-7. [View Abstract]
  5. D'Alessandro V, Muscarella LA, Copetti M, Zelante L, Carella M, Vendemiale G. Molecular detection of neuron-specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer. Cell Oncol. 2008. 30(4):291-7. [View Abstract]
  6. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010 Aug. 9(8):776-85. [View Abstract]
  7. Aguirre-Cruz L, Charuel JL, Carpentier AF, et al. Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases. J Neurooncol. 2005 Jan. 71(1):39-41. [View Abstract]
  8. Saiz A, Graus F, Dalmau J. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol. 1999 Nov. 46(5):774-7. [View Abstract]
  9. Sharshar T, Auriant I, Dorandeu A, et al. Association of herpes simplex virus encephalitis and paraneoplastic encephalitis - a clinico-pathological study. Ann Pathol. 2000 May. 20(3):249-52. [View Abstract]
  10. Foster AR, Caplan JP. Paraneoplastic limbic encephalitis. Psychosomatics. 2009 Mar-Apr. 50(2):108-13. [View Abstract]
  11. Adam VN, Marin D, Budincevic H, Mrsic V, Goranovic T, Tonkovic D. [Paraneoplastic limbic encephalitis]. Acta Med Croatica. 2012 Mar. 66(1):29-32. [View Abstract]
  12. Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol. 2008 Sep 15. 201-202:159-62. [View Abstract]
  13. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999 Feb. 45(2):255-8. [View Abstract]
  14. Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008 Oct. 131:2553-63. [View Abstract]
  15. Mihara M, Sugase S, Konaka K, et al. The "pulvinar sign" in a case of paraneoplastic limbic encephalitis associated with non-Hodgkin's lymphoma. J Neurol Neurosurg Psychiatry. 2005 Jun. 76(6):882-4. [View Abstract]
  16. Wingerchuk DM, Noseworthy JH, Kimmel DW. Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography. Neurology. 1998 Nov. 51(5):1504-7. [View Abstract]
  17. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007 May 4. 2:22. [View Abstract]
  18. Dropcho EJ. Paraneoplastic Diseases of the Nervous System. Curr Treat Options Neurol. 1999 Nov. 1(5):417-427. [View Abstract]
  19. Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999 Nov 10. 53(8):1719-23. [View Abstract]
  20. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000 Apr. 68(4):479-82. [View Abstract]
  21. Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van 't Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006 Jan. 253(1):16-20. [View Abstract]
  22. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005 Aug. 128(Pt 8):1764-77. [View Abstract]
  23. Bakheit AM, Kennedy PG, Behan PO. Paraneoplastic limbic encephalitis: clinico-pathological correlations. J Neurol Neurosurg Psychiatry. 1990 Dec. 53(12):1084-8. [View Abstract]
  24. Compta Y, Valldeoriola F, Urra X, Gómez-Ansón B, Rami L, Tolosa E, et al. Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. Mov Disord. 2007 Apr 15. 22(5):736-8. [View Abstract]
  25. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004 Aug. 127(Pt 8):1831-44. [View Abstract]
  26. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006 Mar. 11(3):292-305.
  27. de Beukelaar JW, Sillevis Smitt PA, Hop WC, Kraan J, Hooijkaas H, Verjans GM, et al. Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes. Eur J Neurol. 2007 Dec. 14(12):1383-91. [View Abstract]
  28. de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol. 2008 Mar. 195(1-2):164-70. [View Abstract]
  29. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul. 123 ( Pt 7):1481-94. [View Abstract]
  30. Inuzuka T. Autoantibodies in paraneoplastic neurological syndrome. Am J Med Sci. 2000 Apr. 319(4):217-26. [View Abstract]
  31. Provenzale JM, Barboriak DP, Coleman RE. Limbic encephalitis: comparison of FDG PET and MR imaging findings. AJR Am J Roentgenol. 1998 Jun. 170(6):1659-60. [View Abstract]
  32. Sabater L, Gomez-Choco M, Saiz A, Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol. 2005 Dec 30. 170(1-2):186-90. [View Abstract]
  33. Scaravilli F, An SF, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol. 1999 Apr. 9(2):251-60. [View Abstract]
  34. Tani T, Tanaka K, Idezuka J, Nishizawa M. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol. 2008 May 30. 196(1-2):166-9. [View Abstract]
  35. Vincent A. Antibodies associated with paraneoplastic neurological disorders. Neurol Sci. 2005 May. 26 Suppl 1:S3-4. [View Abstract]
  36. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004 Mar. 127(Pt 3):701-12. [View Abstract]
  37. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999 Jun 10. 340(23):1788-95. [View Abstract]

Paraneoplastic encephalomyelitis.

Paraneoplastic encephalomyelitis.

Mesial temporal hyperintensity demonstrated on T2-weighted (left) and fluid-attenuated inversion recovery (FLAIR, right) MRI.

Paraneoplastic encephalomyelitis.

Paraneoplastic encephalomyelitis.

Mesial temporal hyperintensity demonstrated on T2-weighted (left) and fluid-attenuated inversion recovery (FLAIR, right) MRI.